These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 39419042)

  • 1. Extension and Further Replication of the Reliability, Criterion Validity, and Treatment Sensitivity of the PANSS10 and PANSS20 for Pediatric Trials.
    Langfus JA; Youngstrom EA; Daniel D; Busner J; Findling RL
    J Child Adolesc Psychopharmacol; 2024 Oct; ():. PubMed ID: 39419042
    [No Abstract]   [Full Text] [Related]  

  • 2. An Optimized Version of the Positive and Negative Symptoms Scale (PANSS) for Pediatric Trials.
    Findling RL; Youngstrom EA; McClellan JM; Frazier JA; Sikich L; Daniel DG; Busner J
    J Am Acad Child Adolesc Psychiatry; 2023 Apr; 62(4):427-434. PubMed ID: 36526163
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reliability, validity and ability to detect change of the clinician-rated Personal and Social Performance scale in patients with acute symptoms of schizophrenia.
    Patrick DL; Burns T; Morosini P; Rothman M; Gagnon DD; Wild D; Adriaenssen I
    Curr Med Res Opin; 2009 Feb; 25(2):325-38. PubMed ID: 19192977
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Factors Associated with Symptom Stabilization that Allow for Successful Transition from Once-Monthly Paliperidone Palmitate to Three-Monthly Paliperidone Palmitate: A Post Hoc Analysis Examined Clinical Characteristics in Chinese Patients with Schizophrenia.
    Li X; Ye C; Zhang W; Jia M; Wang G
    CNS Drugs; 2024 Jan; 38(1):55-65. PubMed ID: 38190077
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Disparity between General Symptom Relief and Remission Criteria in the Positive and Negative Syndrome Scale (PANSS): A Post-treatment Bifactor Item Response Theory Model.
    Anderson AE; Reise SP; Marder SR; Mansolf M; Han C; Bilder RM
    Innov Clin Neurosci; 2017 Dec; 14(11-12):41-53. PubMed ID: 29410936
    [No Abstract]   [Full Text] [Related]  

  • 6. Relapse in clinically stable adult patients with schizophrenia or schizoaffective disorder: evidence-based criteria derived by equipercentile linking and diagnostic test accuracy meta-analysis.
    Siafis S; Brandt L; McCutcheon RA; Gutwinski S; Schneider-Thoma J; Bighelli I; Kane JM; Arango C; Kahn RS; Fleischhacker WW; McGorry P; Carpenter WT; Falkai P; Hasan A; Marder SR; Schooler N; Engel RR; Honer WG; Buchanan RW; Davidson M; Weiser M; Priller J; Davis JM; Howes OD; Correll CU; Leucht S
    Lancet Psychiatry; 2024 Jan; 11(1):36-46. PubMed ID: 38043562
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clozapine combined with different antipsychotic drugs for treatment-resistant schizophrenia.
    Barber S; Olotu U; Corsi M; Cipriani A
    Cochrane Database Syst Rev; 2017 Mar; 3(3):CD006324. PubMed ID: 28333365
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impaired insight in schizophrenia: impact on patient-reported and physician-reported outcome measures in a randomized controlled trial.
    Lysaker PH; Weiden PJ; Sun X; O'Sullivan AK; McEvoy JP
    BMC Psychiatry; 2022 Aug; 22(1):574. PubMed ID: 36031632
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Item response analysis of the Positive and Negative Syndrome Scale.
    Santor DA; Ascher-Svanum H; Lindenmayer JP; Obenchain RL
    BMC Psychiatry; 2007 Nov; 7():66. PubMed ID: 18005449
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Brief Clinical Assessment Scale for Schizophrenia (BCASS): Development, Validity, and Reliability Study.
    Yildiz M; Incedere A; Gürcan MB; Osman E
    Noro Psikiyatr Ars; 2022; 59(1):14-20. PubMed ID: 35317498
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of paliperidone extended-release in schizophrenia patients with prominent affective symptoms.
    Canuso CM; Turkoz I; Sheehan JJ; Bossie CA
    J Affect Disord; 2010 Jan; 120(1-3):193-9. PubMed ID: 19552963
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Paliperidone extended release: a review of its use in the management of schizophrenia.
    Chwieduk CM; Keating GM
    Drugs; 2010 Jul; 70(10):1295-317. PubMed ID: 20568835
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Validation of Chinese Version of Positive and Negative Syndrome Scale-6 in Clinical Setting: A Preliminary Study.
    Li L; Ma H; Wang X; Meng E
    Psychiatry Clin Psychopharmacol; 2021 Dec; 31(4):386-391. PubMed ID: 38765651
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Developing a machine learning-based short form of the positive and negative syndrome scale.
    Lin GH; Liu JH; Lee SC; Wu BJ; Li SQ; Chiu HJ; Wang SP; Hsieh CL
    Asian J Psychiatr; 2024 Apr; 94():103965. PubMed ID: 38394743
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Validity and Reliability Study of Turkish Version of Clinical Assessment Interview for Negative Symptoms (CAINS).
    Vayisoğlu S; Karahan S; Gürel ŞC; Yağcioğlu AEA
    Noro Psikiyatr Ars; 2024; 61(1):59-65. PubMed ID: 38496217
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of End Point Definition and Randomized Clinical Trial Duration in Clinical Trials of Schizophrenia Medications.
    Younis IR; Gopalakrishnan M; Mathis M; Mehta M; Uppoor R; Zhu H; Farchione T
    JAMA Psychiatry; 2020 Oct; 77(10):1064-1071. PubMed ID: 32609294
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of aripiprazole lauroxil in patients with acute schizophrenia as assessed by the Positive and Negative Syndrome Scale-supportive analyses from a Phase 3 study.
    Citrome L; Risinger R; Cutler AJ; Du Y; Zummo J; Nasrallah HA; Silverman BL
    CNS Spectr; 2018 Aug; 23(4):284-290. PubMed ID: 28625204
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reliability, validity and ability to detect change of the PANSS negative symptom factor score in outpatients with schizophrenia on select antipsychotics and with prominent negative or disorganized thought symptoms.
    Edgar CJ; Blaettler T; Bugarski-Kirola D; Le Scouiller S; Garibaldi GM; Marder SR
    Psychiatry Res; 2014 Aug; 218(1-2):219-24. PubMed ID: 24809242
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Linking PANSS negative symptom scores with the Clinical Global Impressions Scale: understanding negative symptom scores in schizophrenia.
    Leucht S; Barabássy Á; Laszlovszky I; Szatmári B; Acsai K; Szalai E; Harsányi J; Earley W; Németh G
    Neuropsychopharmacology; 2019 Aug; 44(9):1589-1596. PubMed ID: 30836381
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.